Biotech 2050 Podcast

Synopsis: Host Rahul Chaturvedi leads an insightful conversation with Dr. Kristin Yarema, President and CEO of Poseida Therapeutics. Kristin shares the inspiring journey of her career, from her roots in science to leadership roles in big pharma, culminating in her move to biotech entrepreneurship. She reflects on pivotal experiences at Novartis and Amgen, her deep-seated passion for oncology and autoimmune diseases, and the exciting leap into the field of cell therapy. Kristin unveils Poseida’s innovative genetic engineering toolkit and the company’s advancements in allogeneic cell therapies, spotlighting their potential to revolutionize treatment for conditions like multiple myeloma. She delves into the challenges and opportunities within the cell therapy space, underscoring Poseida's strategic partnerships and commitment to transformative solutions. With candid reflections on the lessons learned as a first-time CEO, Kristin offers valuable insights on fostering cohesive company culture and shares career advice for aspiring biotech professionals. An essential listen for anyone drawn to biotech innovation, the future of cell therapy, and leadership strategies at the intersection of cutting-edge technology and patient care. Biography: Dr. Yarema was appointed President and Chief Executive Officer of Poseida and named to the Board of Directors in January 2024. She joined Poseida as President, Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. Prior to Poseida she served as Chief Commercial Officer at Atara Biotherapeutics, where she led the commercialization of EBVALLO™️, which became the world’s first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma. Previously Dr. Yarema held a series of U.S. and global commercial leadership roles at Amgen, including most recently Vice President & Therapeutic Area Head for Global Product Strategy & Commercial Innovation in Hematology-Oncology. Earlier in her career, Dr. Yarema worked at Novartis and McKinsey & Company. Dr. Yarema holds a Ph.D. in Chemical Engineering from University of California, Berkeley and is a graduate of Stanford University, where she earned a B.S. in Chemical Engineering and a B.A. in English. She is an officer and member of the board of directors of the Alliance for Regenerative Medicine and serves on the board of directors of the Celiac Disease Foundation.

Synopsis: In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company’s pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined solutions. Bharatt and Eric share their professional journeys and key insights, emphasizing the importance of simplicity and unwavering commitment to impactful ideas. The episode delves into the story behind Karuna Therapeutics, highlighting the challenges of obtaining funding and skepticism from the industry before its success with a groundbreaking schizophrenia drug. Bharatt and Eric underline the importance of patient-centered innovation and reflect on the lessons learned, including overcoming obstacles with persistence. They also discuss the need for more efficient pathways in drug development and share a glimpse into PureTech’s upcoming projects. Biography: Bharatt Chowrira, PhD, JD, is the chief executive officer and a member of the board of directors at PureTech. Dr. Chowrira has been a member of the PureTech management team since March 2017, leading various departments including Operations, Finance and Business Development. Dr. Chowrira plays a key role in the Founded Entity fundraisings and provide strategic guidance as a Board member to many Founded Entities, including co-founding Seaport Therapeutics. Prior to joining PureTech, he held various leadership roles including Chief Executive Officer, President, Chief Operating Officer and General Counsel in multiple biotech companies over the past 30+ years, including Auspex Pharmaceuticals Inc., which was acquired by Teva Pharmaceuticals for $3.5 billion and Sirna Therapeutics that was acquired by Merck for $1.1 billion and as a Vice President at Merck & Co. Dr. Chowrira received a JD from the University of Denver’s Sturm College of Law, a PhD in molecular biology from the University of Vermont College of Medicine, an MS in molecular biology from Illinois State University and a BS in microbiology from the UAS, Bangalore, India. Eric Elenko, PhD, is the president at PureTech where he has led the development of a number of programs, including three that have received US FDA approvals (EndeavorRx, Plenity and Cobenfy). Dr. Elenko plays a key role in the Founded Entity drug discovery and fundraisings, including co-founding Seaport Therapeutics. Prior to joining PureTech, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in biology from Swarthmore College and his PhD in biomedical sciences from the University of California, San Diego.

Synopsis: Rob Williamson, CEO of Triumvira, joins Biotech 2050 host, Rahul Chaturvedi, to discuss his dynamic career from economics to biotech, tackling the volatile capital markets, and navigating high-stakes decisions in cell therapy. He shares insights on therapeutic developments in cell therapy, the pressures of solid tumor research, and the evolving biotech ecosystem. A deep dive into biotech board dynamics, funding strategies, and the potential of AI in healthcare, Rob offers invaluable lessons and forward-thinking perspectives on life sciences and patient care innovation. Biography: Robert F. Williamson, III has been active in building biotechnology companies and shareholder value for over two decades. He currently is the President and COO of Triumvira Immunologics. Previously, he was the CBO of OncoMyx, an oncolytic virus company, and CEO of BioTheryX, a protein degradation therapeutics company, raising a $100M crossover round and preparing the company for an IPO. Prior to BioTheryX, Mr. Williamson served as CEO of both PharmAkea and ATXCo, oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea’s acquisition by Galecto and ATXCo’s acquisition by Blade Therapeutics. Prior, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi. Mr. Williamson also serves as a director and adviser for foundations, private, and public companies. Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a Partner with The Boston Consulting Group and a Research Assistant for the Federal Reserve Board. He received a BA in economics from Pomona College and an MBA from Stanford.

Biotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, which targets Parkinson's disease by aiming for disease modification rather than symptom management. Gene also discusses the challenges of biotech leadership, running clinical trials, and navigating the financial landscape, highlighting the dynamic intersection of science, business, and innovation in neurodegenerative diseases.

Synopsis: Discover how Bitterroot Bio is poised to revolutionize cardiovascular health in this captivating conversation between host Rahul Chaturvedi and CEO Pavan Cheruvu. Pavan opens up about his inspiring journey from engineering to leading a biotech company at the forefront of cardio-immunology. Learn how his visionary leadership is driving innovative solutions to combat atherosclerosis—one of the world’s deadliest diseases. Delve into Bitterroot Bio's cutting-edge approach, blending scientific breakthroughs with bold strategies to create life-saving treatments while overcoming the hurdles of drug development in an ever-changing biotech landscape. Biography: Dr. Pavan K. Cheruvu is the President and Chief Executive Officer at Bitterroot Bio. Prior to joining Bitterroot, Dr. Cheruvu was an early member of the executive team at Roivant Sciences and served as President and CEO of Sio Gene Therapies. Over the course of his career, he has worked with multiple biotechnology and medical device companies, as well as in the public sector, with focus areas spanning neurology, oncology, women’s health, and cardiology. Dr. Cheruvu previously worked as a management consultant at McKinsey & Company, where he focused on R&D strategy and transformation for biopharmaceutical firms across North America, Asia, and Europe. Dr. Cheruvu holds a BS in biomedical engineering, electrical engineering, and chemistry from Duke University and an MSc in computer science from the University of Oxford, where he was a Rhodes Scholar. He went on to earn an MD from Harvard Medical School and MIT. Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training as a clinical fellow in cardiovascular medicine at the University of California, San Francisco. He currently resides in the San Francisco Bay Area with his wife and daughter. He serves on the Executive Leadership Team of the American Heart Association’s Research Roundtable, and the Board of Advisors of Life Sciences Cares Bay Area.

Synopsis: In this episode of Biotech 2050, Alex Martin, CEO of Abcuro, sits down with host Rahul Chaturvedi to share his inspiring journey from aspiring actor to biotech trailblazer. Alex reveals how his unique background shaped his leadership approach as he drives Abcuro’s groundbreaking work on Inclusion Body Myositis (IBM), a rare muscle disease with no current treatments. He offers valuable insights for biotech CEOs on navigating the complexities of fundraising, building mission-driven teams, and fostering productive relationships with boards. Tune in to discover how Alex is leading Abcuro to the forefront of biotech innovation and making a profound impact on patient lives. Biography: Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard.

Synopsis: Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport’s cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug development. Abe also shares his dynamic leadership journey, offering insights into the biotech industry’s future and how innovative approaches are delivering life-changing treatments. Don’t miss this powerful discussion on the future of precision medicine and the hope it brings to patients with neurological conditions. Biography: Abe brings nearly two decades of biopharmaceutical industry experience to Rapport. He served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston. He earned his bachelor’s degree from Ithaca College and Master of Business Administration from Suffolk University’s Sawyer School of Management.

Synopsis: Explore the forefront of biotech innovation as host Rahul Chaturvedi interviews Dr. Dave Bearss, Co-Founder & CEO of Halia Therapeutics, in this engaging episode of Biotech 2050. Dr. Bearss shares the story behind Halia’s pioneering genetic discoveries and their mission to tackle Alzheimer’s disease. Learn about the science driving breakthrough therapies that target neuroinflammation, offering hope in the fight against neurodegenerative disorders. Packed with insights and inspiration, this episode is a must-listen for anyone interested in the future of healthcare and biotech innovation. Biography: Dr. David J. Bearss, a serial entrepreneur and pharmaceutical innovator, has over two decades of experience spanning academic and industrial roles. His expertise lies at the intersection of structure-based small-molecule drug discovery and the utilization of genetic model systems for drug discovery. Dr. Bearss's career is marked by significant achievements, with a strong foundation in translational research focused on drug advancement to the clinic and using genetic markers for predictive drug sensitivity. Notably, Dr. Bearss has discovered 16 compounds that have successfully navigated from discovery in the lab to IND into clinical development. His entrepreneurial experience is evident through his roles as the co-founder of eight biotechnology companies. More importantly, his unwavering commitment to advancing novel drug development truly sets him apart. Before taking on his role as chief scientific officer at Halia in January 2021 and assuming the CEO position in March 2022, Dr. Bearss served as the CEO of Tolero Pharmaceuticals, an organization later acquired by Sumitomo Dainippon Pharma in 2017. His tenure as chief scientific officer at Montigen Pharmaceuticals, followed by its acquisition by SuperGen Inc., demonstrates his dedication to driving early-stage drug discovery and development. At SuperGen, he continued to develop his expertise in these critical areas. Dr. Bearss's academic career is equally impressive. It led to his founding role as the Center for Investigational Therapeutics Co-Director at the Huntsman Cancer Institute. He also held academic positions as an Associate Professor in the Department of Oncological Sciences at the University of Utah and as an Associate Professor of Physiology and Developmental Biology at Brigham Young University, demonstrating his deep knowledge and expertise in these fields. Dr. Bearss's academic career began with a Ph.D. in cell biology from the University of Texas Health Science Center in San Antonio, Texas, and a post-doctoral fellowship at the Institute for Drug Development at the Cancer Therapy and Research Center also in Texas. He has won several awards for his entrepreneurial and scientific achievements, including the Utah Governor's Medal of Science and BIO Utah Entrepreneur of the Year.

Synopsis: In this episode, host Rahul Chaturvedi interviews Sarah Boyce, President & CEO of Avidity Biosciences, as she shares her dynamic journey from big pharma to leading groundbreaking advancements in RNA therapeutics. Sarah delves into overcoming drug delivery challenges, the transformative potential of genetic medicine, and Avidity’s mission to redefine rare disease treatments. She also offers candid insights on leadership, the importance of cultivating a strong company culture, and balancing personal well-being for long-term success. This episode is essential for those eager to explore the future of biotech and the next wave of medical innovation. Biography: Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company's successful Series C funding round and IPO. She continues to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three therapies into clinical development and the expansion of the broad utility of the company’s proprietary RNA technology. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah was named a Healthcare Technology Report Top 25 Biotech CEO in 2022 and has been named one of Fiercest Women in Life Sciences. Sarah currently serves as a member of the board of directors at OmniAb, Inc., Contineum Therapeutics, Inc., and Abcuro, Inc. Sarah holds a BSc (Hons) degree in microbiology from the University of Manchester, England.

Synopsis: Step into the future of biotech as host Rahul Chaturvedi delves into an exclusive conversation with Fabrice Chouraqui, CEO of Cellarity, as he unveils the groundbreaking ways AI is revolutionizing drug discovery. Fabrice will take you behind the scenes of Cellarity’s trailblazing approach, revealing how their pioneering technology is accelerating drug development and creating a synergy-driven powerhouse. Tune in for a front-row seat to the next era of biotech innovation and gain exclusive insights from a leader at the cutting edge of the industry. Biography: Fabrice Chouraqui is CEO-partner of Flagship Pioneering and CEO of Cellarity. Cellarity is a Flagship-backed company developing game-changing medicines that are unreachable with traditional methods of drug discovery. By harnessing the power of AI and single-cell omics data, Cellarity’s approach allows them to see disease biology others can’t. The Cellarity platform links biology and chemistry to multi-omics data and enables the design of medicines against cellular dysfunction – an approach applicable to a vast array of diseases to offer new hope to patients in need. Fabrice is an experienced global pharmaceutical executive with a passion for driving the progress of medical sciences and bringing innovation to patients. He has deep experience across the business spectrum, from R&D to commercial leadership, business development and investor communications. Fabrice has led the launch of breakthrough treatments in a number of areas, including oncology, immunology, neuroscience and cardiovascular. Prior to Cellarity, Fabrice was president of the U.S. Pharmaceuticals business for Novartis, where he was credited with transforming the organization to adapt to a new market environment and turning around its performance. He also represented Novartis on the board of BIO. Fabrice earned an MBA from INSEAD in France and a Doctorate in Pharmacy, a Post-Graduate Degree in Quality Assurance of Medicines, and a MSc in Biological and Medicinal Sciences from University of Paris V. Born in Paris, France, he is fluent in English and French.

Synopsis: Get ready for an insightful conversation as host Rahul Chaturvedi connects with John Alam, CEO of CervoMed, to uncover the revolutionary advancements transforming dementia treatment, with a spotlight on Dementia with Lewy Bodies (DLB). John shares his remarkable journey from practicing medicine to leading cutting-edge biotech innovations, shedding light on the bold breakthroughs in neurodegenerative research and the intense, high-stakes world of clinical trials. This episode reveals how CervoMed is not just advancing dementia care but redefining it, proving that resilience and bold thinking are the keys to success in biotech. Biography: John Alam serves as the Chief Executive Officer at CervoMed, co-founding the company (formerly known as EIP Pharma) in 2014. John is an industry leader in translational medicine with over 30 years of experience creating value to help build companies through clinical development success. Until May 2014, he was therapeutic area head for diseases of aging at Sanofi, where he led all discovery and development activities directed at Alzheimer’s disease, as well as a number of other age-related diseases including sarcopenia/frailty, osteoarthritis, chronic pain and many others. From 1997 to 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals, including Chief Medical Officer and Executive Vice President, Medicines Development. At Vertex, he played major roles in the development of novel innovative medicines for HIV, Hepatitis C and Cystic Fibrosis. Prior to Vertex, Alam led clinical development of Avonex (interferon beta-1a) for multiple sclerosis at Biogen from 1991 to 1997. John is a member of the board of directors of the Alliance for Aging Research (AAR), a Washington, D.C. based non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. He received a MD from Northwestern University School of Medicine and a BS in Chemical Engineering from the Massachusetts Institute of Technology. In addition, he completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.

Synopsis: Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, appears on this insightful episode of Biotech 2050 with host Rahul Chaturvedi. Renée shares her unconventional journey from investment banking to biotech leadership, underscoring the crucial role of capital markets and regulatory strategies. The discussion explores the unique challenges of developing treatments for rare diseases, strategic decisions on indication selection, and the complexities of managing a global team. Highlighting the importance of continuous learning and curiosity, Renée provides invaluable insights into navigating the fast-paced biotech industry. Tune in to discover the strategic and operational nuances of leading a successful biotech company in today's dynamic environment. Biography: CEO since 2017. Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was the European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of software for financial services. Renée took up BA in Finance from Stockholm School of Economics and finished her MBA from INSEAD.

Synopsis: In this engaging episode, host, Rahul Chaturvedi welcomes Marshall Fordyce, Founder and CEO of Vera Therapeutics, to discuss his transformative journey from physician to biotech entrepreneur. Marshall shares the story behind Vera Therapeutics' strategic pivot to focus on IG nephropathy and their development of atacicept, a promising B-cell modulator. He provides valuable insights into the biotech industry's landscape, emphasizing the importance of scientific rigor, adaptability, and maintaining a lean, effective operating model. Marshall's enthusiasm for advancing autoimmune disease treatments and his advice for aspiring entrepreneurs make this a must-listen episode. Biography: Dr. Fordyce brings more than 15 years’ experience leading teams in drug discovery, development, clinical translation, and commercialization of new treatments. Before founding Vera, Fordyce was the founder and CEO of gene-editing company Trucode Gene Repair, Inc., having previously served as an entrepreneur in residence at Kleiner Perkins Caufield and Byers. Earlier in his career, Fordyce served as Senior Director of clinical research at Gilead Sciences, Inc., where he contributed to seven new drug approvals and served as project lead for Gilead’s TAF/GENVOYA development program. With subspecialty training in infectious disease from Columbia University Vagelos College of Physicians and Surgeons, Fordyce was previously Chief Resident at NYU Bellevue and spent two years as a translational research fellow at Rockefeller University. Fordyce currently serves on the Board of Directors of the Albert and Mary Lasker Foundation. He received his BA from Harvard University and his MD from Harvard Medical School.

Synopsis: Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company. She elaborates on Meira’s cutting-edge approach to genetic medicines, focusing on the development of innovative therapies for non-inherited diseases. Zandy discusses the unique challenges and opportunities that arise in the biotech sector, shedding light on the strategies Meira employs to navigate this complex landscape. Biography: Alexandria Forbes, Ph.D. is the President and CEO of MeiraGTx (NASDAQ: MGTX). MeiraGTx is a vertically integrated gene therapy company with core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. The company is developing innovative gene therapy products to cost effectively treat a range of serious medical disorders, with clinical programs currently in the eye, salivary gland and CNS. Prior to founding MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., a biopharmaceutical company, from September 2013 to April 2015.Before joining the biotech industry, she spent 10 years as a healthcare investor at Sivik Global Partners (Argus Partners) and Meadowvale Partners. At Sivik, Dr. Forbes was responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics public equities and was portfolio manager of the Sivik Global Life Science Fund, a long-biased public markets fund investing in biotechnology companies globally. During her time as a biotechnology investor, Dr. Forbes covered over 300 companies and gained expertise in biotechnology business strategies and clinical drug development as well as a wide range of disease areas. Particular areas of focus included HIV, HCV, diabetes, obesity, autoimmune disorders, cancer, Alzheimer’s disease, kidney disease and liver disease. Before entering the hedge fund industry, Dr. Forbes was an academic scientist studying the regulation of stem cell identity and different aspects of embryogeneis. She was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, Dr. Forbes was a research fellow at Duke University and at the Carnegie Institute at Johns Hopkins University where she studied the role of the hedgehog gene and its signaling pathway in the Drosophila embryo and adult. Dr. Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and attained a double first degree in Natural Sciences from Cambridge University, UK. Dr. Forbes serves on the Board of Directors of MeiraGTx, and as a Trustee and Director of the Selfridges Group Foundation, the European arm of the Weston Brain Institute, a charity supporting research into neurodegenerative diseases with the aim of speeding the time to the development of disease modifying treatments for these currently intractable diseases, particularly Alzheimer’s.

Synopsis: Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, and the unique strategies that have driven Nimbus's success. Jeb discusses the evolution of biotech financing, the importance of taking bold risks, and the innovative approaches Nimbus employs in drug development. He also shares insights on building a resilient team, navigating challenging capital markets, and fostering a collaborative ecosystem in biotech. This episode provides valuable lessons for aspiring biotech leaders and a deep dive into the intricacies of managing a cutting-edge biotech company. Biography: Jeb Keiper, M.S., M.B.A., has served as our President and Chief Executive Officer and as a member of our board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Mr. Keiper has overseen the discovery and development of three programs into clinical testing across a range of indications, over $400M raised in equity funding, executed deals worth over $7B, and the return of over $4B in gains back to equity holders. Prior to joining Nimbus, Mr. Keiper served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc (NYSE: GSK)) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in Oncology, including the Novartis-GSK Oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Mr. Keiper was a consultant at McKinsey & Company starting in September 2000-2002, then September 2004 to 2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998. Mr. Keiper currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc., and ROME Therapeutics, Inc. Mr. Keiper received two B.S. degrees, one in Chemistry and one in Chemical Engineering, as well as an M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management with joint program in Biomedical Enterprises with the Harvard Medical School.

Synopsis: Sujal Patel, co-founder and CEO of Nautilus Biotechnology, discusses their innovative work in proteomics and its impact on drug development. Sujal shares his transition from tech to biotech, the formation of Nautilus with Parag Mallick, and their revolutionary approach using multi-affinity probes. The conversation highlights the importance of proteomics in drug discovery, the broad applications of their technology, and the significance of product-market fit and fiscal discipline in building a sustainable business. Biography: Sujal Patel is the co-founder of Nautilus Biotechnology, a life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to democratize access to the proteome and, in doing so, enable fundamental advancements across human health and medicine. Sujal founded Isilon Systems in 2001, a storage company built for the future of unstructured, file-based data. In 2006, Isilon completed one of the most successful initial public offerings of the year. EMC (since acquired by Dell) acquired Isilon in December 2010 for $2.6 Billion, the largest acquisition in EMC’s history. Sujal served as the president of EMC’s Isilon Storage Division from the acquisition until November 2012, driving significant revenue growth, market expansion, and organizational scale. Prior to EMC and Isilon, Sujal served in various engineering roles at RealNetworks, Inc., in part as the chief architect behind the company’s second-generation core media delivery system. Sujal holds nineteen patents in the areas of storage, networking, and media delivery and five patents for innovations related to the development of Nautilus Biotechnology’s technology. He is a well-known speaker on entrepreneurship and has received a variety of industry awards. Currently, Sujal serves on the board of directors at Qumulo and Rainier Scholars and helps direct the philanthropic efforts of his family’s foundation. He graduated from the University of Maryland College Park in 1996 with a degree in computer science.

Synopsis: In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr. Leuchter shares his journey from clinical training to leadership at Neurvati. The conversation covers the convergence of neurology and psychiatry, advanced technologies in drug development, and addressing unmet medical needs in neuroscience. Join us for insights into the future of biotech and developments in neuroscience. Biography: Dr. Bruce Leuchter brings deep-rooted, wide-ranging experience to his role as President and CEO at Neurvati, spanning neuroscience, clinical neuropsychiatry, biotechnology equity research, healthcare investment banking and entrepreneurship. His expertise captures all aspects of building and leading a neuroscience company, and his experiences have generated deep empathy for the patient journey. Across his many roles in the clinic, industry, and beyond, Dr. Leuchter has maintained a passion for knowledge and has aimed to purposefully apply that knowledge to help patients suffering from diseases of the brain and nervous system. A physician by training and neuropsychiatrist by specialty, Dr. Leuchter completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a voluntary faculty appointment in the Department of Psychiatry. Dr. Leuchter has also held multiple financial services roles including biotechnology equity research at Goldman Sachs, healthcare investment banking at Credits Suisse, and biotechnology mergers and acquisitions at PJT Partners, all of which drive a nuanced understanding of the biotechnology industry and particularly the neuroscience ecosystem. Dr. Leuchter is Co-Founder and Founding Neuropsychiatrist of a digital therapeutics company, Click Therapeutics, which specializes in the treatment of neurological and psychiatric disorders. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, as a member of the Life Science Institute Leadership Council at the University of Michigan, as a member of the Advisory Board at Michigan Drug Discovery, and as a Business Advisory Board member at FOXG1 Research Foundation.

Synopsis: In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. He discusses the groundbreaking advancements in antibody-drug conjugates (ADCs), particularly highlighting the success of their HER2-targeted therapies. Ken shares his career journey, emphasizing the importance of building a team of passionate individuals who are eager to innovate and make a difference. He also touches on the significance of strategic partnerships in accelerating drug development and ensuring global access to life-saving treatments. The conversation offers valuable insights into the future of cancer therapies and the dynamic landscape of the biotech industry. Biography: Ken Keller is the Chairman of the Board, President, and Chief Executive Officer of Daiichi Sankyo, Inc. He is also the Head of the Global Oncology Business responsible for leading the overarching company strategy of ensuring innovative medicines are available to patients with cancer around the world. With more than 30 years of experience in the pharmaceutical industry, Ken has led multi-billion dollar businesses in both U.S. and Europe while working to unify cross-functional teams to create a global infrastructure – enabling the commercial success of Daiichi Sankyo oncology and specialty medicines. Through leadership roles in multiple markets, across cultures and within different healthcare systems, Ken has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth. With more than 20 years of oncology experience, Ken had a longstanding career at Amgen where he held several leadership roles, with increasing global and commercial responsibility, including Vice President and General Manager, Bone Health Business Unit. Prior to joining Daiichi Sankyo, Ken served as Chief Operating Officer at Spectrum Pharmaceuticals, where he held global responsibility for leading commercial operations, medical and clinical development, regulatory, quality, safety and pharmaceutical operations. Ken is motivated by passion for innovation and compassion for patients, which is at the core of everything he instills within his leadership teams. Developing and coaching high-performing global teams that can have a profound impact on patient lives and leading an organization that is responsible for helping to change the standard of care for the oncology community is a privilege he is incredibly grateful for.

Synopsis: In this episode of Biotech2050, Praveen Tipirneni, CEO of Morphic Therapeutics, shares insights on Morphic’s strategic IPO, the rising interest in autoimmune treatments, the journey of their alpha 4 beta 7 program, and maintaining a conservative yet opportunistic approach in biotech. He also discusses the importance of building a strong team, navigating the complex biotech landscape, and the value of enjoying the journey. Biography: Praveen Tipirneni, MD, MBA is Chief Executive Officer of Morphic Therapeutic Inc. Previously, he was Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, a position in which he served from 2002 until the company’s acquisition by Merck in 2015. In his time at Cubist, he was a member of the clinical group working on the Cubicin NDA (skin and skin structure infections) and sNDA (Staph. Bacteremia and Endocarditis) teams. He was head of business development since January 2006. Prior to joining Cubist, Dr. Tipirneni worked at Sun Microsystems in corporate strategy, Covad Communications in Corporate Strategy, and Deltagen in business development. He also served time as a 1st Lieutenant in the U.S. Army. Dr. Tipirneni received a bachelor’s degree from MIT in mechanical engineering and an M. D. from McGill University. After completing his post-graduate residency in Internal Medicine at University of Illinois, Chicago, he received his MBA from the University of Pennsylvania’s Wharton School of Business in healthcare finance.

Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. Robert also talks about his experience serving on boards and emphasizes the importance of core values in shaping organizational culture. He highlights his approach to hiring, focusing on finding individuals who are passionate about making an impact over titles. Overall, the discussion provides valuable insights into the evolving landscape of cancer treatment. Biography: Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he served as Senior Vice President of Business Development at Bavarian Nordic, where he was primarily responsible for conducting a $975 million transaction with Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset, and served as Head of Business Development and Medical Affairs for Cadence Pharmaceuticals. Robert also worked at Frazier Healthcare Ventures, a leading life sciences venture capital firm, where he was involved in several pharmaceutical and biotechnology investments including Cadence Pharmaceuticals (purchased by Mallinckrodt), Incline Therapeutics (purchased by The Medicines Company), Alnara Pharmaceuticals (purchased by Eli Lilly), and Collegium Pharmaceuticals. Robert also has strategy consulting experience at the Boston Consulting Group and has general surgical training. He holds an MBBS (Doctor of Medicine) from the University of Western Australia and an MBA with honors from Columbia Business School. Robert serves as the Board Chair of Enara Bio, a UK-based biotechnology company focused on non-classical HLA targets for immuno-oncology approaches. He is also a member of the Executive Committee of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.